AlphAIAlphAI — Financial news for AI agents
investing.comOCT 162 min read$BLLN

BillionToOne CEO Oguzhan Atay sells $1.09 million in stock

BillionToOne CEO Oguzhan Atay sold $1.09M in stock on Oct 14-15, 2026, including direct sales of $829K and indirect sales by his spouse. Shares sold at $98.00-$102.83. BLLN stock is up 24% in six months but down from $102.73. InvestingPro flags it as overvalued. The company has a $4.85B market cap, P/E of 137.73, and 90% revenue growth. Q2 earnings beat expectations with $0.15 EPS and 64% revenue growth. Canaccord Genuity initiated coverage with a $120 target.

Original reporting
investing.com
Published Oct 16, 2026, 11:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 18, 2026, 12:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The insider sale introduces short‑term downside risk despite positive fundamentals.

02

Market read

The news is primarily relevant to BLLN shareholders and short‑term traders.

03

What to watch

Recent earnings beat and analyst coverage upgrade may offset selling pressure.

Relevance 4/10Novelty 3/10Timing: after-hours

Background

BillionToOne reported strong Q2 earnings and received a buy rating from Canaccord Genuity, but the CEO's insider sales were disclosed shortly after.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

CEO Oguzhan Atay sold $1.09 million of BLLN shares under a Rule 10b5‑1 plan on Oct 14‑15, 2026.

Expected impact

downward pressure as market prices in the insider sale

Evidence & confidence

The sale represents a sizable insider divestment, which often signals potential downside.

Market effects

Sector

Minimal impact on the broader AI/diagnostics sector.

Regional

Limited to U.S. investors tracking BLLN.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine liquidity planning, not a negative signal.

Key entities

  • Company
    BillionToOne, Inc.

    NASDAQ‑listed AI diagnostics firm.

  • Executive
    Oguzhan Atay

    Chairman and CEO of BillionToOne.

Read at source← All news

Related articles

OCT 7
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com2 min
OCT 7
$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

globenewswire.com2 min
AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
AUG 5
$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

SEC EDGAR 8-K7 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min